🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Degarelix

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  2. Delandistrogene moxeparvovec-rokl

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  3. Dental stent

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  4. Descartes-08

    Cartesian Therapeutics

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  5. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  6. Dexamethason 4 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, TAZEMETOSTAT, CC-92480, Mekinist 2 mg film-coated tablets, Dexamethason 4 mg GALEN®, Mekinist 0.5 mg film-coated tablets, BET-Inhibitor, CC-92480

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  7. Dexamethasone

    United Therapeutics Europe Ltd

    Voice Change

    phase 2 small molecule active

    1 trial

  8. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  9. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 2 small molecule active

    1 trial

  10. Dimethyl fumarate

    Xuanwu Hospital, Beijing

    Intracerebral Hemorrhage

    phase 2 small molecule terminated

    1 trial

  11. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  12. Doravirine

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    phase 2 small molecule active

    1 trial

  13. Doxycycline

    Hospital Authority, Hong Kong

    Tuberculosis, Meningeal

    phase 2 small molecule active

    1 trial

  14. Doxycycline EG 200 mg Tabletten

    The George Institute

    Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)

    phase 2 small molecule active

    1 trial

  15. Dupilumab

    Regeneron UK Limited

    Atopic Keratoconjunctivitis

    phase 2 small molecule active

    1 trial

  16. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  17. Dupilumab

    Regeneron UK Limited

    Eosinophilic Gastritis (EoG)

    phase 2 small molecule active

    1 trial

  18. Dupilumab

    Regeneron UK Limited

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  19. Dupilumab

    Regeneron UK Limited

    Pruritis

    phase 2 small molecule active

    1 trial

  20. Dupilumab

    Regeneron UK Limited

    Peanut Allergy

    phase 2 small molecule completed

    2 trials

  21. Dupilumab

    Regeneron UK Limited

    Allergies Food Milk

    phase 2 small molecule terminated

    1 trial

  22. Dupilumab

    Regeneron UK Limited

    Alopecia Areata

    phase 2 small molecule active

    2 trials

  23. Dupilumab

    Regeneron UK Limited

    Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  24. Dupilumab

    Regeneron UK Limited

    Asthma, Allergic

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources